Literature DB >> 20829830

Pushing the envelope on HIV-1 neutralization.

Joseph G Joyce, Jan ter Meulen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20829830     DOI： 10.1038/nbt0910-929

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  10 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

Review 3.  Accessing the human repertoire for broadly neutralizing HIV antibodies.

Authors:  Philip W Hammond
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

4.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.

Authors:  Gayathri Bommakanti; Michael P Citron; Robert W Hepler; Cheryl Callahan; Gwendolyn J Heidecker; Tariq Ahmad Najar; Xianghan Lu; Joseph G Joyce; John W Shiver; Danilo R Casimiro; Jan ter Meulen; Xiaoping Liang; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

Review 7.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

8.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

9.  A method for identification of HIV gp140 binding memory B cells in human blood.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Bruce D Walker; Florencia Pereyra; Emily Cutrell; Michael S Seaman; John R Mascola; Richard T Wyatt; Hedda Wardemann; Michel C Nussenzweig
Journal:  J Immunol Methods       Date:  2008-12-25       Impact factor: 2.303

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728
  10 in total
  3 in total

1.  HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

Authors:  Susan M Schader; Susan P Colby-Germinario; Peter K Quashie; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Daniela Moisi; Thibault Mespléde; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 2.  "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies.

Authors:  Jordan D Dimitrov; Michel D Kazatchkine; Srinivas V Kaveri; Sebastien Lacroix-Desmazes
Journal:  PLoS Pathog       Date:  2011-06-16       Impact factor: 6.823

3.  Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy.

Authors:  Yael Ben-Nun; Emmanuelle Merquiol; Alexander Brandis; Boris Turk; Avigdor Scherz; Galia Blum
Journal:  Theranostics       Date:  2015-04-27       Impact factor: 11.556
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.